Clinical Evidence of Effective Hemophilia A Bleeding Control

Powerful Bleeding Prevention − Prophylaxis1

The efficacy of wilate in routine preventive care (prophylaxis) was evaluated in a prospective, open-label, multi-center clinical study in which adult subjects aged 21 and older (50 participants) and adolescent subjects aged 12-15 years (5 participants) were treated during 6 months of prophylaxis with a dose of 20-40 IU/kg (mean dose, 32 IU/kg)*

*IU = International Unit

ZERO Median ABR* (Annual Bleeding Rate)

  • ZERO Median ABR ALL BLEEDS
    • range in adults, 0-15.69
    • range in adolescents, 0-2
  • ZERO Median ABR SPONTANEOUS BLEEDS
    • range in adults, 0-11.76
    • range in adolescents, 0-0

*per subject, adults and adolescents

Number of Bleeding Episodes*

  • 77% had zero (30/55) or one (12/55) bleeding episodes
  • 14% had two (4/55) or three (4/55) bleeding episodes
  • 9% (5/55) had 5 or more bleeding episodes.

*per subject, adults and adolescents


Effective Bleeding Resolution − On Demand1


96% of Subjects Were Managed with 3 or Fewer Injections

  • Bleeds were managed with one injection in 63% of patients; with two injections in 21%; and with three injections in 12.3%
  • Mean dose per injection, 34 IU/kg
84% of bleeding episodes were treated successfully, with efficacy judged as GOOD or EXCELLENT.
CTA Circles
icon-clip-board Created with Sketch.

Review the safety and tolerability profile of wilate in the treatment of hemophilia A

Read More

References:
  1. wilate Full Prescribing Information. Hoboken, NJ: Octapharma; rev September 2019.